Texas Children's Hospital
Welcome,         Profile    Billing    Logout  
 645 Trials 
597 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dunkel, Ira
NCT03904862: Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Recruiting
1/2
66
US
CX 4945, Silmitasertib sodium
Pediatric Brain Tumor Consortium, Senhwa Biosciences, Inc., National Cancer Institute (NCI), St. Jude Children's Research Hospital, National Cancer Institute/NIH/DHHS (NCI)
Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma
12/29
02/30
NCT03389802: Phase I Study of APX005M in Pediatric Central Nervous System Tumors

Active, not recruiting
1
32
US
APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
Pediatric Brain Tumor Consortium, American Lebanese Syrian Associated Charities, Pyxis Oncology, Inc, Solving Kids' Cancer, Ty Louis Campbell Foundation, A Kids' Brain Tumor Cure Foundation, National Cancer Institute (NCI)
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS), Diffuse Intrinsic Pontine Gliomas (DIPG), Medulloblastoma
09/23
09/24
NCT03033992: Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

Recruiting
N/A
80
US
Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Optune System (NovoTTF-200A System), Concurrent Optune and RT followed by Optune System alone
Pediatric Brain Tumor Consortium, National Cancer Institute (NCI), NovoCure Ltd., American Lebanese Syrian Associated Charities (ALSAC)
Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
07/32
09/32
Sanchez, Pablo J
NCT06061081: A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Suspended
2
26
Europe, US, RoW
VH3739937, Placebo
ViiV Healthcare
HIV Infections
11/24
11/24
NCT04318587: Assessment of Donor Derived Cell Free DNA and Utility in Lung Transplantation

Terminated
N/A
40
US
Allosure
Pablo Sanchez, CareDx
Lung Transplant Failure and Rejection
12/22
12/23
Abrams, Steven A
AMISTAD, NCT04801134: Interventions to Manage Food Insecurity and Inappropriate Feeding Practices Related to the COVID-19 Pandemic

Not yet recruiting
N/A
50
US
Education, Community Resources
University of Texas at Austin, Perrigo Company
Food Insecurity, Children, Only, Covid19
03/22
05/22
Carrum, George
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
Heslop, Helen E
NCT05305040: Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Terminated
2/3
451
Europe, Canada, US, RoW
Posoleucel (ALVR105), Viralym-M, Placebo
AlloVir
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
01/24
01/24
CHARIOT, NCT04268706: Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
2
97
US
CD30.CAR-T, Fludarabine, Fludara, Bendamustine, Bendeka
Tessa Therapeutics
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
05/25
03/37
ACTION, NCT05352828: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Active, not recruiting
1b
15
US
Nivolumab, Opdivo, Autologous CD30.CAR-T, CD30-directed CAR-T cells, Fludarabine, Fludara, Bendamustine, Bendeka, Treanda
Tessa Therapeutics, Bristol-Myers Squibb
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
12/25
12/37
Bollard, Catherine
SUN-RAY, NCT06358638: Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY

Recruiting
2
12
US
Daratumumab, Darzalex, Alemtuzumab, Campath-1H, Sirolimus, Rapamune, Total Body Irradiation, TBI
Children's National Research Institute, Alberta Children's Hospital, The Hospital for Sick Children, Levine Children's Hospital, Ann & Robert H Lurie Children's Hospital of Chicago, Nationwide Children's Hospital, Children's Hospital at Montefiore, Doris Duke Charitable Foundation, Janssen Pharmaceuticals
Sickle Cell Disease
09/44
09/54
Fisher, Michael
NCT06161974: Study of Olutasidenib and Temozolomide in HGG

Not yet recruiting
2
60
Europe, Canada, US, RoW
Olutasidenib + TMZ
Rigel Pharmaceuticals, Nationwide Children's Hospital
High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
06/29
06/35
INSPIRE-NF1, NCT06541847: A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients with Neurofibromatosis Type 1

Recruiting
2
20
US
HLX-1502
Healx Limited
Neurofibromatosis Type 1
07/26
08/27
NCT02840409 / 2017-001982-26: Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

Active, not recruiting
2
109
Canada, US, RoW
Vinblastine, Bevacizumab, Avastin
The Hospital for Sick Children, Hoffmann-La Roche
Low Grade Glioma
07/24
08/26
NCT05843253: Study of Ribociclib and Everolimus in HGG and DIPG

Recruiting
2
100
Europe, Canada, US, RoW
Ribociclib, Kisqali, Everolimus, Afinitor
Nationwide Children's Hospital, Novartis
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
08/28
08/34
NCT03605550: A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

Active, not recruiting
1
64
US
PTC596, Radiotherapy
Nationwide Children's Hospital, PTC Therapeutics
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
03/24
03/29
NCT06333899: Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Not yet recruiting
1
15
Europe, Canada, US, RoW
Lorlatinib, LOBRENA, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation
Nationwide Children's Hospital, Pfizer
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma, Glioblastoma, Glioblastoma Multiforme, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Midline Glioma, H3K27-altered
09/27
09/34
Shneider, Benjamin
NCT02055768: Safety and Efficacy Study of the Intestinal Bile Acid Transport (IBAT) in the Reduction of Pruritus in ALGS

Not yet recruiting
2
24
US, Canada
LUM001 70 ug/kg/day, Intestinal Bile Acid Transport (IBAT) Inhibitor, Placebo, LUM001 140 ug/kg/day
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Lumena Pharmaceuticals, Inc.
Pruritus, Alagille Syndrome
02/15
05/15
Shenoy, Shalini
ABA3, NCT04380740: Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

Recruiting
2
160
US
Placebo, saline, Abatacept, orencia
Boston Children's Hospital, Bristol-Myers Squibb
Graft Vs Host Disease
04/25
04/25
NCT03068819: Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
110
US
CIML NK Cell Infusion, CD3+ T Cell Product Infusion
Washington University School of Medicine, National Cancer Institute (NCI), Wugen, Inc., Children's Discovery Institute
Acute Myeloid Leukemia
10/28
10/28
NCT06247787: A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recruiting
1
36
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Echocardiography, EC, Fludarabine, Fluradosa, Hydrocortisone Sodium Succinate, (11beta)-21-(3-Carboxy-1-oxopropyl)-11,17-dihydroxypregn-4-ene-3,20-dione, Monosodium Salt, A-Hydrocort, Buccalsone, Corlan, Cortisol Sodium Succinate, Cortop, Efcortelan, Emergent-EZ, Flebocortid, Hidroc Clora, Hycorace, Hydro-Adreson, Hydrocort, Hydrocortisone 21-Sodium Succinate, Hydrocortisone Na Succinate, Kinogen, Nordicort, Nositrol, Sinsurrene, Sodium hydrocortisone succinate, Solu-Cortef, Solu-Glyc, Imetelstat, GRN 163L, GRN-163L, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Lumbar Puncture, LP, Spinal Tap, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039
Children's Oncology Group, Geron Corporation, National Cancer Institute (NCI)
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia
06/26
06/26
Nguyen, Trung
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
Rubnitz, Jeffrey
NCT05955261: A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Recruiting
2
70
US
Venetoclax, Venclextra, ABT-99, Azacitidine, Mylosar, Vidaza, Cytarabine, Ara-C, Cytosar-U®, Gemtuzumab Ozogamicin, Mylotarg, Daunorubicin Hydrochloride, FI-6339, L-lyxo-Hexopyranoside, Fludarabine Phosphate, SH T 586, Idarubicin Hydrochloride, IMI-30, Zavedos, Mitoxantrone Hydrochloride, Neotalem, Pralifan, Novantrone, Etoposide, VP-16, Vepesid®, Gilteritinib, Xospata
St. Jude Children's Research Hospital, AbbVie
Acute Myeloid Leukemia
12/26
03/34
T2017-002, NCT03817320 / 2019-001947-28: PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, not recruiting
1/2
31
US, RoW
Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
Therapeutic Advances in Childhood Leukemia Consortium, Takeda, Children's Hospital Los Angeles
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
12/24
06/25
SELCLAX, NCT04898894: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Recruiting
1
42
US
Venetoclax, Venclextra®, ABT-199, Selinexor, KPT-330, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar®, Fludarabine, Fludara®, Fludarabine phosphate, 2-fluoro-ara-AMP, Filgrastim, G-CSF, Methotrexate, MTX, amethopterin, Trexall®, methotrexate/hydrocortisone/cytarabine, ITMHA, Intrathecal triples
St. Jude Children's Research Hospital, Karyopharm Therapeutics Inc, AbbVie, Gateway for Cancer Research
Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
07/23
06/27
NCT06177067: Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Recruiting
1
24
US
Revumenib, SNDX-5613, Venetoclax, Venclextra®, Azacitidine, VIDAZA®, 5-azacitidine, intrathecal (IT) chemotherapy, ITMHA, methotrexate/hydrocortisone/cytarabine, Cytarabine, Ara-C, Cytosar®, Methotrexate, MTX, Trexall®
St. Jude Children's Research Hospital, Syndax Pharmaceuticals
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
01/26
07/26
NCT05918913: Expanded Access Program for Revumenib

Available
N/A
US
Revumenib, SNDX-5613
Syndax Pharmaceuticals
Relapsed/Refractory Acute Leukemia
 
 
Hutchinson, Raymond J
NCT02879643: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Recruiting
1
36
Canada, US, RoW
Marqibo
Therapeutic Advances in Childhood Leukemia Consortium, Spectrum Pharmaceuticals, Inc
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
08/21
12/22
Zage, Peter
NCT03611595: Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Recruiting
1
18
US
Cabozantinib, CABOMETYX, 13-cis-retinoic acid, isotretinoin
Peter Zage, Exelixis
Solid Tumor
08/25
08/26
Shaw, James AM
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
PMS-001, NCT05025241: An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome

Completed
2
18
US
NNZ-2591, Cyclo-L-Glycyl-L-2-Allylproline
Neuren Pharmaceuticals Limited
Phelan-McDermid Syndrome
11/23
11/23
PTHS-001, NCT05025332: An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome

Completed
2
16
US
NNZ-2591, Cyclo-L-Glycyl-L-2-Allylproline
Neuren Pharmaceuticals Limited
Pitt Hopkins Syndrome
02/24
05/24
AS-001, NCT05011851: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

Completed
2
17
RoW
NNZ-2591, Cyclo-L-Glycyl-L-2-Allylproline
Neuren Pharmaceuticals Limited
Angelman Syndrome
05/24
07/24
PWS-001, NCT05879614: An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome

Withdrawn
2
20
US
NNZ-2591, Cyclo-L-Glycyl-L-2-Allylproline
Neuren Pharmaceuticals Limited
Prader-Willi Syndrome
06/25
06/25
Andropoulos, Dean B
ANA01, NCT03427736: Anesthetics and Analgesics in Children

Recruiting
N/A
460
Canada, US
Ketorolac Tromethamine, Toradol, Hydromorphone, Hydromorphone hydrochloride, Dilaudid, Ketamine, Ketamine Hydrochloride, Oxycodone, Oxycodone Hydrochloride, Morphine, Morphine Sulfate
Kanecia Obie Zimmerman, The Emmes Company, LLC
Anesthesia, Pain
06/25
06/25
Jefferies, John L
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial

Hourglass Feb 2024 - Dec 2024 : Data from SUMMIT trial in participants with heart failure with preserved ejection fraction and obesity
Completed
3
731
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
07/24
07/24
Ramos, Carlos
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Terminated
3
205
Europe, RoW
Plitidepsin, Dexamethasone, Remdesivir, Favipiravir
PharmaMar
COVID-19 Infection
03/23
03/23
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
NCT05556824: Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

Recruiting
2
156
US
MHS-1031, Panosyl-isomaltooligosaccharide, Placebo
Microbiome Health Sciences, VBHRC Virginia Catalyst
Gastroesophageal Reflux
07/25
07/25
ACTION, NCT05352828: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Active, not recruiting
1b
15
US
Nivolumab, Opdivo, Autologous CD30.CAR-T, CD30-directed CAR-T cells, Fludarabine, Fludara, Bendamustine, Bendeka, Treanda
Tessa Therapeutics, Bristol-Myers Squibb
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
12/25
12/37
ANCHOR2, NCT05487651: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

Recruiting
1
36
US
KUR-502, CD19.CAR-aNKT cells
Athenex, Inc.
NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL
12/23
12/24
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
Shulman, Robert
NCT06004596: Establishing a Pediatric Reference Range for the 13C-Spirulina Gastric Emptying Breath Test (GEBT)

Completed
N/A
182
US
13C-Spirulina Gastric Emptying Breath Test (GEBT), 13C-Spirulina Gastric Emptying Breath Test (GEBT) - repeat
Cairn Diagnostics, Medical College of Wisconsin, Baylor College of Medicine
Gastroparesis
01/24
09/24
Degar, Barbara
NCT02425904: Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Active, not recruiting
2
25
Canada, US
Clofarabine, Clofarex, Clolar
Dana-Farber Cancer Institute, Sanofi, St. Baldrick's Foundation, Cookies for Kids' Cancer, North American Consortium for Histiocytosis
Langerhans Cell Histiocytosis
01/20
01/25
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/24
12/29
NCT04551131: Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Active, not recruiting
1/2
62
US
Ruxolitinib, Jakafi®, Dexamethasone, Decadron®, Hexadrol®, Dexone®, Dexameth®, Etoposide, Etoposide Phosphate, VePesid®, Etopophos®, VP-16
St. Jude Children's Research Hospital, Incyte Corporation, North American Consortium for Histiocytosis, Cures Within Reach
Hemophagocytic Lymphohistiocytosis
08/25
08/26
Roth, David R
SY-1425-201, NCT02807558 / 2017-000783-14: A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Checkmark Combination trial with SY-1425 in AML/MDS
Dec 2018 - Dec 2018: Combination trial with SY-1425 in AML/MDS
Checkmark Initial clinical data from cohorts
Dec 2018 - Dec 2018: Initial clinical data from cohorts
Completed
2
155
Europe, US
Tamibarotene, SY-1425, Azacitidine, Vidaza, Daratumumab, Darzalex
Syros Pharmaceuticals
Acute Myeloid Leukemia, Myelodysplastic Syndrome
01/23
01/23
Kellermayer, Richard
NCT03325855: Fecal Microbiota Transplant National Registry

Recruiting
N/A
4000
Canada, US
None - Observational, Observational
American Gastroenterological Association, OpenBiome, University of California, San Diego, Commure, University of Pennsylvania, University of Minnesota, Loyola University Chicago
Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
08/27
08/27
Leary, Sarah
NCT06161974: Study of Olutasidenib and Temozolomide in HGG

Not yet recruiting
2
60
Europe, Canada, US, RoW
Olutasidenib + TMZ
Rigel Pharmaceuticals, Nationwide Children's Hospital
High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
06/29
06/35
NCT05843253: Study of Ribociclib and Everolimus in HGG and DIPG

Recruiting
2
100
Europe, Canada, US, RoW
Ribociclib, Kisqali, Everolimus, Afinitor
Nationwide Children's Hospital, Novartis
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
08/28
08/34
NCT03690869 / 2023-000604-19: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Calendar Jan 2025 - Dec 2025: From trial n pediatrics with solid tumors
Terminated
1/2
57
US
cemiplimab (monotherapy), REGN2810, Libtayo, cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
Regeneron Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium
Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
05/23
05/23
AAML1921, NCT04258943 / 2015-002916-34: Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Active, not recruiting
1/2
60
US
Bosutinib
Children's Oncology Group, Erasmus Medical Center, Dutch Childhood Oncology Group, Innovative Therapies for Children with Cancer, Pfizer
Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia
07/28
07/28
NCT02367144: Phase 1 Study of BLZ-100 in Pediatric Subjects With CNS Tumors

Not yet recruiting
1
27
US
BLZ-100, Tumor Paint
Blaze Bioscience Inc.
Central Nervous System Tumors
05/16
08/16
NCT02962167: Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

Completed
1
34
US
Modified Measles Virus, MV-NIS, Modified Measles Virus Lumbar Puncture, MV-NIS LP
Sabine Mueller, MD, PhD, No More Kids With Cancer, The Matthew Larson Foundation for Pediatric Brain Tumors, Vyriad, Inc., Mayo Clinic
Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
05/23
05/23
NCT03605550: A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

Active, not recruiting
1
64
US
PTC596, Radiotherapy
Nationwide Children's Hospital, PTC Therapeutics
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
03/24
03/29
NCT06333899: Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Not yet recruiting
1
15
Europe, Canada, US, RoW
Lorlatinib, LOBRENA, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation
Nationwide Children's Hospital, Pfizer
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma, Glioblastoma, Glioblastoma Multiforme, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Midline Glioma, H3K27-altered
09/27
09/34
Martinez, Caridad A
BRIDGE, NCT05787574: A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Recruiting
2
39
US
Emapalumab, Fludarabine and Dexamethasone, Stem Cell Transplant
Memorial Sloan Kettering Cancer Center, Sobi, Inc.
Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases
03/27
03/27
Investigator, Principal
OCEAN, NCT04986982 / 2020-001175-32: OpiCapone Effect on Motor Fluctuations and pAiN

Completed
4
144
Europe
Opicapone 50 mg, BIA 9-1067, Placebo
Bial - Portela C S.A., Bial - Portela & Ca, S.A.
Parkinson Disease
02/24
02/24
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Completed
4
140
RoW
Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox
Daiichi Sankyo
COPD Exacerbation Acute
09/24
09/24
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Active, not recruiting
3
165
Europe, Canada, US, RoW
Macitentan, ACT-064992, Standard-of-care
Actelion
Pulmonary Arterial Hypertension
08/24
07/25
TROPION-LUNG01, NCT04656652 / 2020-004643-80: Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations

Hourglass Jul 2023 - Dec 2023 : Acceptance of regulatory submission for 2L+ NSCLC with or without actionable genomic alterations (based on TROPION-Lung01 trial)
Apr 2023 - Jun 2023: Topline results from TROPION-LUNG01 trial for metastatic NSCLC
Active, not recruiting
3
590
Europe, Canada, Japan, US, RoW
DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel
Daiichi Sankyo, AstraZeneca
Non-small Cell Lung Cancer
05/24
06/25
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin
Daiichi Sankyo, Merck Sharp & Dohme LLC
Small Cell Lung Cancer
04/27
02/29
HERTHENA-Lung02, NCT05338970 / 2021-005879-40: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Active, not recruiting
3
586
Europe, Canada, Japan, US, RoW
Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy
Daiichi Sankyo, Merck Sharp & Dohme LLC
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
05/24
06/26
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

Not yet recruiting
3
1500
US
Transdermal system containing progestin
Mylan Pharmaceuticals Inc
Female Contraception
03/27
04/27
VDJ001-RA-Ⅲ, NCT06726096: Phase III Trial of VDJ001 in Patients with Moderate-to-severe Active Rheumatoid Arthritis

Not yet recruiting
3
615
RoW
Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Beijing VDJBio Co., LTD.
Rheumatoid Arthritis (RA)
12/25
12/26
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

Not yet recruiting
3
78
Europe
Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Swedish Orphan Biovitrum, PSI CRO
Severe Haemophilia A
08/26
08/26
frontMIND, NCT04824092 / 2020-002990-84: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Calendar Jul 2025 - Dec 2025: Primary analysis data from frontMIND trial in combination with Revlimid for newly diagnosed DLBCL
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at EHA 2021
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at ASCO 2021
Active, not recruiting
3
899
Europe, Canada, Japan, US, RoW
Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
Incyte Corporation
Diffuse Large B-cell Lymphoma
06/25
05/26
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Completed
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Active, not recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Recruiting
3
110
RoW
68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET
Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd.
Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma
12/25
07/26
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Jan 2024 - Dec 2024: Acceptance of of regulatory submission for HER2+ post neo-adjuvant breast cancer (DESTINY-Breast05 trial)
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

Active, not recruiting
3
93
Europe, RoW
Efanesoctocog alfa, BIVV001
Swedish Orphan Biovitrum, Syneos Health
Hemophilia A, Severe
05/26
05/26
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer

Recruiting
3
1170
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
08/27
08/27
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Recruiting
3
250
Europe, US, RoW
Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu®
Daiichi Sankyo, AstraZeneca
Breast Cancer
10/27
10/27
Tropion-Lung08, NCT05215340 / 2021-002555-10: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Jan 2024 - Dec 2024: Data from TROPION-Lung08 trial for advanced or metastatic NSCLC
Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L metastatic NSCLC (based on TROPION Lung08 trial)
Recruiting
3
740
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
02/28
04/28
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Recruiting
2/3
650
US
Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo
Bicara Therapeutics
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
04/28
07/29
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery

Recruiting
2/3
336
Europe
Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar
Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center
Injury of Ureter During Surgery (Disorder)
10/25
11/25
ESTRELLA, NCT04764448 / 2020-003313-35: A Study of Belcesiran in Patients With AATLD

Terminated
2
16
Europe, Canada, US, RoW
Belcesiran, Placebo
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Alpha 1-Antitrypsin Deficiency
12/23
05/24
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Recruiting
2
115
US
Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid
AbbVie, AbbVie
Neovascular Age-Related Macular Degeneration (nAMD)
10/25
08/26
RGX-314-2103, NCT04832724: RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Completed
2
60
US
RGX-314
AbbVie
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration
10/23
03/24
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS)

Recruiting
2
40
Europe
MC2-25 cream, MC2-25 vehicle
MC2 Therapeutics
Vulvar Lichen Sclerosus
11/24
11/24
StrataSOMA, NCT04765202: StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

Completed
2
13
US
AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA)
Stratatech, a Mallinckrodt Company
Full Thickness Thermal Burn
03/24
03/24
HERTHENA-PanTumor01, NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
2
400
Europe, Japan, US, RoW
HER3-DXd, Patritumab Deruxtecan, U3-1402
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
06/25
04/26
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Completed
2
145
Europe, US, RoW
KPL-404, Placebo
Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd.
Arthritis, Rheumatoid
02/24
05/24
EAD501, NCT05607615 / 2022-003819-29: A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease

Recruiting
2
90
US
Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline
Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc.
Alzheimer's Disease
03/24
03/24
NCT05569252 / 2022-000676-19: A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

Completed
2
65
Europe, US
DS-1211b, Placebo
Daiichi Sankyo, PXE International
Pseudoxanthoma Elasticum
11/23
11/23
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors

Recruiting
2
520
Europe, Japan, US, RoW
Ifinatamab deruxtecan, I-DXd
Daiichi Sankyo, Merck Sharp & Dohme LLC
Recurrent or Metastatic Solid Tumors
07/28
07/28
IDeate-Lung01, NCT05280470 / 2022-000503-13: Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Active, not recruiting
2
187
Europe, Japan, US, RoW
Ifinatamab Deruxtecan (I-DXd), DS-7300a
Daiichi Sankyo, Merck Sharp & Dohme LLC
Extensive-stage Small-cell Lung Cancer
01/25
04/25
SPG302-SCZ-201, NCT06442462: Study of SPG302 in Adults With Schizophrenia

Recruiting
2
32
RoW
SPG302, Placebo
Spinogenix
Schizophrenia
06/25
10/25
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo

Recruiting
2
120
US
Nimacimab injection, Nimacimab placebo injection, semaglutide injection
Skye Bioscience, Inc., Bird Rock Bio Sub, Inc.
Obesity
08/25
01/26
ALM-488-004, NCT06662097: A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery

Recruiting
2
64
US
Bevonescein, ALM-488
Alume Biosciences, Inc.
Surgery, Nerve Injury, Imaging
06/25
09/25
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)

Withdrawn
2
25
RoW
CST-103, CST-107, matching placebo
CuraSen Therapeutics, Inc.
Freezing of Gait Symptoms in Parkinson's Disease
12/24
03/25
REJOICE-PanTumor01, NCT06660654: A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors

Not yet recruiting
2
200
Japan, US
Raludotatug deruxtecan, R-DXd
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumors
09/27
09/27
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Recruiting
2
240
US
COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1
GeoVax, Inc., National Cancer Institute (NCI)
COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
12/26
12/27
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study

Not yet recruiting
2
26
Europe
TCP-25 gel, Vehicle (placebo)
Xinnate AB
Epidermolysis Bullosa (EB)
06/26
06/26
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Recruiting
2
146
Japan, US, RoW
TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel
Toray Industries, Inc
Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
08/25
08/25
NCT05205330 / 2020-002435-29: CR6086/AGEN2034 Combination in Stage IV pMMR - MSS CRC, and Other Metastatic GI Cancers

Recruiting
1/2
55
Europe
CR6086, vorbipiprant, AGEN2034, balstilimab
Rottapharm Biotech, Agenus Inc.
Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer
03/25
09/26
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

Active, not recruiting
1/2
26
US
DS-7011a, Placebo
Daiichi Sankyo
Systemic Lupus Erythematosus
04/25
04/25
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
190
Europe, US
ASTX029
Taiho Oncology, Inc.
Solid Tumor, Adult
08/24
12/25
 

Download Options